1. Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia. Issue 12 (11th July 2022) Authors: Furze, Rebecca C.; Molnar, Judit; Parr, Nigel J.; Ahmad, Faiz; Henry, Yvette; Howe, David; Singh, Rajendra; Toal, Martin; Bassil, Anna K.; Bernard, Sharon G.; Davis, Robert P.; Gibson, Adele; Maller, N. Claire; Sharp, Catriona; Tough, David F.; Prinjha, Rab K.; Lewis, Huw D. Other Names: Wong Ian guestEditor.; Dewildt Saskia guestEditor. Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 12(2022) Page Start: 5238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗